Kirkland Advises CapVest on Recapitalization of Curium Pharma
Kirkland & Ellis is advising CapVest Partners on the recapitalization of Curium Pharma, a leading producer of radiopharmaceuticals, via a new continuation vehicle (CV). The CV values Curium at approximately $7 billion, representing the largest transaction in nuclear medicine globally. The transaction elicited wide support from existing and new institutional investors across the U.S., Europe, the Middle East and APAC.
Completion of the transaction is expected in Q1 2026 and is subject to customary regulatory approvals. CapVest will remain the controlling shareholder of Curium.
Read the transaction announcement
The Kirkland team includes investment funds lawyers Ted Cardos, Andy Shore, Arie Scharf, Luke Scott, Kahwing Fung, Rhett McPhie, Stephen Giblin, Sara Kim and Christopher Mathias; corporate lawyers Carlos Gil Rivas, Jeremy Wilkins, Chris Ho, Oliver Weighill, Shawn OHargan, Amanda Gottlieb, Guillaume Nivault, Raam Jeganathan, Simran Johal, Amanda Levi-Acobas, Lucy Parton, Justin Prindle, George Rix and Benjamin Whidborne; tax lawyers Alan Walker, Gal Shemer, Cosmos Fung, David Grenker, Beatriz Capeloa Gil, Abigail Curry and Chloe Rowan; technology & IP transactions lawyers Ben Zeris and Julia Ostendorf; financial services regulatory lawyers Amar Unadkat and Ipsiata Gupta; debt finance lawyers Evgeny Zborovsky, Karen Ford and Michael McNamee; international trade & national security lawyer Erika Krum; sustainability lawyer Lucía Soley Saborío; and derivatives lawyer Drue Santora.
